CTE Stock Overview
Cryosite Limited offers outsourced clinical trials logistic services in Australia.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Cryosite Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.69 |
52 Week High | AU$0.84 |
52 Week Low | AU$0.51 |
Beta | 0.53 |
1 Month Change | 9.52% |
3 Month Change | 14.05% |
1 Year Change | -11.54% |
3 Year Change | 176.00% |
5 Year Change | 1,871.43% |
Change since IPO | 56.82% |
Recent News & Updates
Shareholder Returns
CTE | AU Life Sciences | AU Market | |
---|---|---|---|
7D | 1.5% | 3.3% | 1.3% |
1Y | -11.5% | -22.8% | 11.5% |
Return vs Industry: CTE exceeded the Australian Life Sciences industry which returned -23.3% over the past year.
Return vs Market: CTE underperformed the Australian Market which returned 11.6% over the past year.
Price Volatility
CTE volatility | |
---|---|
CTE Average Weekly Movement | n/a |
Life Sciences Industry Average Movement | 10.0% |
Market Average Movement | 8.8% |
10% most volatile stocks in AU Market | 17.1% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: CTE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CTE's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 25 | n/a | https://www.cryosite.com |
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological, as well as logistics services to the clinical trials, research, and pharmaceutical industries.
Cryosite Limited Fundamentals Summary
CTE fundamental statistics | |
---|---|
Market cap | AU$33.68m |
Earnings (TTM) | AU$1.58m |
Revenue (TTM) | AU$12.62m |
21.4x
P/E Ratio2.7x
P/S RatioIs CTE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CTE income statement (TTM) | |
---|---|
Revenue | AU$12.62m |
Cost of Revenue | AU$4.94m |
Gross Profit | AU$7.68m |
Other Expenses | AU$6.10m |
Earnings | AU$1.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.032 |
Gross Margin | 60.86% |
Net Profit Margin | 12.49% |
Debt/Equity Ratio | 0% |
How did CTE perform over the long term?
See historical performance and comparison